Else Nutrition Expected to Benefit from FDA Regulatory Progress on Infant Formula Protein Standards

Executive Summary

• The U.S. FDA has added Protein Efficiency Ratio (PER) rat bioassay study guidance to its active regulatory agenda, providing clearer standards for protein quality in infant formulas.
• Else Nutrition views this development as a material positive catalyst that reduces regulatory uncertainty and strengthens the pathway for FDA clearance of its plant‑based infant formula in the United States.
• The company expects the clarified PER methodology to enhance its competitive positioning in the multi‑billion‑dollar U.S. infant formula market and attract interest from ESG‑focused investors.

Key Details

• FDA has formally listed Protein Efficiency Ratio (PER) Rat Bioassay Study Guidance as an active topic within its Foods Program regulatory agenda.
• PER is one of the FDA‑recognized methods for demonstrating biological protein quality in infant formulas; existing standards are considered outdated and have created uncertainty for novel protein sources.
• The updated guidance aims to clarify study design, endpoints, and expectations for protein quality validation, giving companies better visibility into scope, timeline, and cost of required preclinical studies.
• Else Nutrition believes the clarification reduces a key regulatory risk associated with launching its plant‑based infant formula in the U.S. market.
• The development aligns with broader federal initiatives such as Operation Stork Speed, which seeks to modernize infant formula oversight and update nutrient standards for the first time since 1998.
• Strategic implications highlighted by Else Nutrition:
• Ability to demonstrate protein quality on a level regulatory playing field versus conventional dairy or soy formulas.
• Positioning to benefit from growing demand for clean‑label, plant‑based nutrition and federal efforts to expand competition in the infant formula market.
• Potential to attract long‑only institutional investors, ESG funds, and growth‑focused capital seeking companies with identifiable regulatory catalysts.
• CEO & Co‑Founder Hamutal Yitzhak stated that the FDA’s progress on PER guidance is a “meaningful inflection point” that sharpens Else’s regulatory roadmap and strengthens confidence in U.S. commercial potential.

Notable Quotes

“The FDA's progress on PER guidance is a meaningful inflection point for Else Nutrition. As clarity increases around the scientific and procedural standards required for novel infant formulas, our regulatory roadmap becomes sharper, more predictable, and increasingly aligned with federal efforts to modernize the U.S. formula market.” – Hamutal Yitzhak, CEO & Co‑Founder

All boilerplate, forward‑looking disclaimer text, and company background sections have been omitted.